December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Preliminary analysis reported manageable safety profile and clinical activity with belantamab mafodotin plus bortezomib/dexamethasone in ongoing phase II trial of pretreated patients with MM.